Shares of these biotech companies are near their five-year highs after some strong performances in 2019.
News & Analysis: Seattle Genetics
Shares of this cancer-focused biotech seem to have "winner" built into their DNA.
These two stocks don't appear to be slowing down anytime soon.
With a newly approved drug and a candidate treatment that the FDA has given its “breakthrough” designation, there's good reason to expect revenue growth.
Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.
The FDA was in a big hurry to make these new therapies available for patients who need them.
Promising new results in breast cancer will be presented at next week's San Antonio Breast Cancer Symposium. Here's what to look for.
The company reported positive results in a late-stage trial for an important drug candidate.
SGEN earnings call for the period ending September 30, 2019.
With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.